Transdermal and Skin-Targeted Drug Delivery

Abstract

French

Background:

The application of therapeutic agents to the skin addresses three general objectives: (a) the treatment of a variety of dermatologic diseases; (b) the “targeted” delivery of drugs to deeper subcutaneous tissues, with a concomitant reduction in systemic exposure; and (c) socalled transdermal administration to elicit a systemic pharmacologic effect.

Objective:

Recently, significant progress towards all three goals has been recorded and the level of research and development activity remains high. We aim to discuss these advances from mechanistic and clinical standpoints.

Results:

For the topical treatment of skin disease, novel vehicles (e.g., stabilized, supersaturated systems and liposomal formulations) have led to dramatic improvements in local drug bioavailability. Transdermal delivery of drugs for systemic effect, though limited in terms of the number of compounds, is perhaps the most commercially successful (in terms of the number of products) of the controlled release technologies. Considerable activity continues to enhance drug delivery (and hence to extend the range of drugs for which transdermal delivery can be used). Existing patches use formulations that contain solvents and adjuvants capable of reducing the barrier function of the skin. Much effort is directed at iontophoresis (electrically enhanced transport), particularly for small peptides that are difficult to administer by other routes. “Reverse iontophoresis” may allow the extraction of glucose (without skin puncture) so that continuous, noninvasive monitoring of blood sugar in diabetics approaches realization.

Conclusion:

In the not too distant future, the skin may also play a role not only in drug delivery, but also with respect to measurements in clinical chemistry.

Get full access to this article

View all access options for this article.

References

Guy

Kalia

Lim

. Drug smuggling — creative ways to cross biological barriers. Chemistry in Britain 1996; 32: 42–45.

Guy

. Current status and future prospects of transdermal drug delivery. Pharm Res 1996; 13:1765–1769.

Elias

. Epidermal barrier: Intracellular lamellar lipid structures, origin, composition and metabolism. J Control Release 1991; 15: 199–208.

Forslind

. A domain mosaic model of the skin barrier. Acta Derm Venereol (Stockh) 1994; 74:1–6.

Scheuplein

Blank

. Permeability of the skin. Physiol Rev 1971; 51:702–747.

Elias

Friend

. The permeability barrier in mammalian epidermis. J Cell Biol 1975; 65:180–191.

Blank

. Cutaneous barriers. J Invest Dermatol 1965; 45: 249–256.

Potts

Francoeur

. Lipid biophysics of water loss through the skin. Proc Natl Acad Sci USA 1990; 87:3871–3873.

Potts

Francoeur

. The influence of stratum corneum morphology on water permeability. J Invest Dermatol 1991; 96: 495–499.

10.

Guy

Hadgraft

. Transdermal drug delivery: The ground rules are emerging. Pharm Int 1985; 6:112–116.

11.

Kalia

Pirot

Guy

. Homogeneous transport in a heterogeneous membrane: Water diffusion across human stratum corneum in vivo. Biophys J 1996; 71: 2692–2700.

12.

Shah

Behl

Flynn

. Principles and criteria in the development and optimization of topical therapeutic products. Skin Pharmacol 1993; 6:72–80.

13.

Addicks

Weiner

Curl

Flynn

. Drug delivery from topical formulations: Theoretical prediction and experimental assessment. In: Osborne

Amann

, eds. Topical drug delivery formulations. New York: Marcel Dekker, 1990:221–244.

14.

Davis

Hadgraft

. The use of supersaturation in topical drug delivery. In: Scott

Guy

Hadgraft

, eds. Prediction of percutaneous penetration, Vol. 2. London: IBC Technical Services, 1991:279–287.

15.

Hadgraft

Wolff

. Physicochemical and pharmacokinetic parameters affecting percutaneous absorption. In: Gurny

Teubner

, eds. Dermal and transdermal drug delivery. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1993:161–172.

16.

Barry

. Properties that influence percutaneous absorption. In: Barry

, ed. Dermatological formulations: Percutaneous absorption. New York: Marcel Dekker, 1983:127–233.

17.

Smith

Maibach

, eds. Percutaneous penetration enhancers. Boca Raton: CRC Press, 1995.

18.

Ghosh

Banga

. Methods of enhancement of transdermal drug delivery. Part 2A. Chemical permeation enhancers. Pharm Technol 1993; 17:62–90.

19.

Weiner

Martin

Riaz

. Liposomes as a drug delivery system. Drug Dev Ind Pharm 1989; 15:1523–1554.

20.

Uster

. Liposome-based vehicles for topical delivery. In: Osborne

Amann

, eds. Topical drug delivery formulations. New York: Marcel Dekker, 1990:327–348.

21.

Lauer

Ramachandran

Lieb

. Targeted delivery to the pilosebaceous unit via liposomes. Adv Drug Deliv Rev 1996; 18:311–324.

22.

Cevc

Blume

Schätzlein

. The skin: A pathway for systemic treatment with patches and lipid-based agent carriers. Adv Drug Deliv Rev 1996; 18:349–378.

23.

Cooper

Patel

. Practical considerations for topical drug formulations with and without enhancers. In: Osborne

Amann

, eds. Topical drug delivery formulations. New York: Marcel Dekker, 1990:1–12.

24.

Ongpipattanakul

Burnette

Potts

. Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharm Res 1991; 8:350–354.

25.

Franz

Lehman

Kagy

. Dimethylsulfoxide. In: Smith

Maibach

, eds. Percutaneous penetration enhancers. Boca Raton: CRC Press, 1995:115–127.

26.

Chien

. Transdermal drug delivery and delivery systems. In: Chien

, ed. Novel drug delivery systems. 2nd ed. New York: Marcel Dekker, 1992:301–380.

27.

Zatz

. Assessment of vehicle factors influencing percutaneous absorption. In: Bronaugh

Maibach

, eds. In vitro percutaneous absorption: Principles, fundamentals and applications. Boca Raton: CRC Press, 1991:51–66.

28.

Ziegenmeyer

. The influence of the vehicle on the absorption and permeation of drugs. In: Brandau

Lippold

, eds. Dermal and transdermal absorption. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1982:73–89.

29.

Martin

Dupont

Samour

. Non-invasive evaluation of the effect of 2n-nonyl-1,3-dioxolane on the cutaneous barrier properties of healthy volunteers. Proceedings of the 21st International Symposium on Controlled Release of Bioactive Materials 1994; 21:407–408.

30.

Wester

Maibach

. Penetration enhancement by skin hydration. In: Smith

Maibach

, eds. Percutaneous penetration enhancers. Boca Raton: CRC Press, 1995:21–28.

31.

Haigh

Smith

. Hydration and topical corticosteroid absorption. In: Smith

Maibach

, eds. Percutaneous penetration enhancers. Boca Raton: CRC Press, 1995:29–34.

32.

Mak

VHW

Potts

Guy

. Does hydration affect intercellular lipid organisation in the stratum corneum. Pharm Res 1991; 8:1064–1065.

33.

Bouwstra

Gooris

Salomondevries

. Structure of human stratum corneum as a function of temperature and hydration — a wide-angle x-ray diffraction study. Int J Pharm 1992; 84:205–216.

34.

Cornwell

Barry

Stoddart

. Wide-angle x-ray diffraction of human stratum corneum — effects of hydration and terpene enhancer treatment. J Pharm Pharmacol 1994; 46: 938–950.

35.

Obata

Tagami

. Electrical determination of water content and concentration profile in a simulation model of in vivo stratum corneum. J Invest Dermatol 1989; 92:854–859.

36.

Zellmer

Pfeil

Lasch

. Interaction of phosphatidylcholine liposomes with the human stratum corneum. Biochim Biophys Acta 1995; 1237:176–182.

37.

Schmid

M-H

Korting

. Therapeutic progress with topical liposome drugs for skin disease. Adv Drug Del Rev 1996; 18:335–342.

38.

Mezei

Gulasekharam

. Liposomes — a selective drug delivery system for topical route of administration: Lotion dosage form. Life Sci 1980; 26:1473–1477.

39.

Vermorken

Hukkelhoven

Vermeesch-Markslag

. The use of liposomes in the topical application of steroids. J Pharm Pharmacol 1984; 36:334–336.

40.

Mills

Kligman

. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol Stockh 1978; 58:555–557.

41.

Foong

Harsanyi

Mezei

. Biodisposition and histological evaluation of topically applied retinoic acid in liposomal cream and gel dosage forms. In: Hanin

, ed. Phospholipids. New York: Plenum Press, 1990:279–282.

42.

Masini

Bonte

Meybeck

. Cutaneous bioavailability in hairless rats of tretinoin in liposomes or gel. J Pharm Sci 1993; 82:17–21.

43.

Gesztes

Mezei

. Topical anesthesia of the skin by liposome-encapsulated tetracaine. Anesth Analg 1988; 67:1079–1081.

44.

Short

Rubas

Paasch

Mrsny

. Transport of biologically active interferon-gamma across human skin in vitro. Pharm Res 1995, 12:1140–1145.

45.

Uchegbu

Florence

. Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry. Adv Colloid Interfacial Sci 1995; 58:1–55.

46.

McNeill

Potts

Francoeur

. Local enhanced topical delivery (LETD) of drugs: Does it truly exist? Pharm Res 1992; 9:1422–1427.

47.

Shaw

. Transdermal therapeutic systems. In: Brandau

Lippold

, eds. Dermal and transdermal absorption. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1982:171–187.

48.

Cleary

. Transdermal delivery systems: A medical rationale. In: Shah

Maibach

, eds. Topical drug bioavailability, bio-equivalence, and penetration. New York: Plenum Press, 1993: 17–68.

49.

Carmichael

. Skin sensitivity and transdermal drug delivery. A review of the problem. Drug Safety 1994; 10:151–159.

50.

Corazza

Mantovani

Virgili

. Allergic contact dermatitis from a Clonidine transdermal drug delivery system. Contact Dermatitis 1995; 32:246.

51.

Doe

Seth

Hebert

. Skin depigmentation related to transdermal Clonidine therapy. Arch Intern Med 1995; 155:2129.

52.

Tyle

. Iontophoretic devices for drug delivery. Pharm Res 1986; 3:318–326.

53.

Tyle

Agrawala

. Drug delivery by phonophoresis. Pharm Res 1989; 6:355–361.

54.

Delgado-Charro

Guy

. Characterization of convective flow during iontophoresis. Pharm Res 1994; 11:929–935.

55.

Pikal

Shah

. Transport mechanism in iontophoresis. II. Electroosmotic flow and transference number measurements for hairless mouse skin. Pharm Res 1990; 7:213–221.

56.

Burnette

. Iontophoresis. In: Hadgraft

Guy

, eds. Transdermal drug delivery: Developmental issues and research initiatives. New York: Marcel Dekker, 1989:247–291.

57.

Ledger

. Skin biological issues in electrically enhanced transdermal delivery. Adv Drug Del Rev 1992; 9:289–307.

58.

Guy

. Effect of iontophoresis on the electrical properties of human skin in vivo. Int J Pharm 1995; 124:137–142.

59.

Kalia

Guy

. The electrical characteristics of human skin in vivo. Pharm Res 1995; 12:1605–1613.

60.

Kalia

Nonato

Guy

. The effect of iontophoresis on skin barrier integrity: Non-invasive evaluation by impedance spectroscopy and transepidermal water loss. Pharm Res 1996; 13:957–960.

61.

Green

Hinz

Cullander

. Iontophoretic delivery of amino acids and amino acid derivatives across the skin in vitro. Pharm Res 1991; 8:1113–1120.

62.

Green

Hinz

Kim

. Iontophoretic delivery of a series of tripeptides across the skin in vitro. Pharm Res 1991; 8: 1121–1127.

63.

Pikal

. Transport mechanism in iontophoresis. I. A theoretical model for the effect of electroosmotic flow on flux enhancement in transdermal iontophoresis. Pharm Res 1990; 7:118–126.

64.

Burnette

Marreo

. Comparison between the iontophoretic and passive transport of thyrotropin-releasing hormone across excised nude mouse skin. J Pharm Sci 1986; 75:738–743.

65.

Green

Hinz

Kim

. Transdermal iontophoresis of amino acids and peptides in vitro. J Control Rel 1992; 21: 187–190.

66.

Sloan

Soltani

. Iontophoresis in dermatology. J Am Acad Dermatol 1986; 15:671–684.

67.

Webster

. Laboratory diagnosis of cystic fibrosis. Crit Rev Clin Lab Sci 1983; 18:313–338.

68.

Maloney

. Local anesthesia obtained via iontophoresis as an aid to shave biopsy. Arch Dermatol 1992; 128:331–332.

69.

Ashburn

Streisand

Zhong

. The iontophoresis of fentanyl citrate in humans. Anesthesiology 1995; 82:1146–1153.

70.

Varghese

Khar

. Enhanced skin permeation of diclofenac by iontophoresis: In vitro and in vivo studies. J Control Rel 1996; 38:21–27.

71.

Schmidt

Binder

Maicheiner

. New treatment of atrophic acne scars by iontophoresis with estriol and tretinoin. Int J Dermatol 1995; 34:53–57.

72.

Mass

Bundgnard

. Prodrugs of peptides. 7. Transdermal delivery of thyrotropin-releasing hormone (TRH) via prodrug. Int J Pharm 1990; 66:39–45.

73.

Sage

. Insulin iontophoresis. In: Sanders

Hendron

, eds. Protein delivery — physical systems. New York: Plenum Press, 1996: (In press).

74.

Miller

Kolaskie

Smith

. Transdermal iontophoresis of gonadotropin-releasing hormone (LHRH) and two analogues. J Pharm Sci 1990; 79:490–493.

75.

Heit

Monteiro-Riviere

Jayes

. Transdermal iontophoretic delivery of luteinizing hormone releasing hormone (LHRH): Effects of repeated administration. Pharm Res 1994; 11:1000–1003.

76.

Lee

Carlson

. The effects of formulation variables on iontophoretic transdermal delivery of leuprolide to humans. Drug Dev Ind Pharm 1993; 19:1557–1571.

77.

Delgado-Charro

Guy

. Iontophoretic delivery of nafarelin across the skin. Int J Pharm 1995; 117:165–172.

78.

Delgado-Charro

Rodríguez-Bayøn

Guy

. Iontophoresis of nafarelin: Effects of current density and concentration on electrotransport in vitro. J Control Rel 1995; 35:35–40.

79.

Hirvonen

Kalia

Guy

. Transdermal delivery of peptides by iontophoresis. Nature Biotech 1996; 14:1710–1713.

80.

Glikfeld

Hinz

Guy

. Noninvasive sampling of biological fluids by iontophoresis. Pharm Res 1989; 6:988–990.

81.

Rao

Glikfeld

Guy

. Reverse iontophoresis: Development of a noninvasive approach for glucose monitoring. Pharm Res 1993; 10:1751–1755.

82.

Rao

Guy

Glikfeld

. Reverse iontophoresis: Non-invasive glucose monitoring in vivo in humans. Pharm Res 1995; 12:1869–1873.

83.

Tamada

Bohannon

NJV

Potts

. Measurement of glucose in diabetic subjects using noninvasive transdermal extraction. Nature Med 1995; 1:1198–1201.

84.

Tsong

. Electroporation of cell membranes. Biophys J 1991; 60:297–306.

85.

Powell

Morgenthaler

Weaver

. Tissue electroporation: Observation of reversible electrical breakdown in viable frog skin. Biophys J 1989; 56:1163–1171.

86.

Prausnitz

Bose

Langer

. Electroporation of mammalian skin: A mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci USA 1993; 90:10504–10508.

87.

Vanbever

De Morre

Préat

. Transdermal delivery of fentanyl by electroporation. II. Mechanisms involved in drug transport. Pharm Res 1996; 13:1360–1366.

88.

Rols

Teissié

. Electropermeabilization of mammalian cells: Quantitative analysis of phenomenon. Biophys J 1990; 58: 1089–1098.

89.

Hibino

Shigemori

Itoh

. Membrane conductance of an electroporated cell analyzed by microsecond imaging of transmembrane potential. Biophys J 1991; 59:209–220.

90.

Chernomordik

Sukharev

Abidor

. Breakdown of lipid bilayer membranes in an electric field. Biochem Biophys Acta 1983; 736:203–213.

91.

Bommannan

Tamada

Leung

. Effect of electroporation on transdermal iontophoretic delivery of luteinizing hormone releasing hormone (LHRH) in vitro. Pharm Res 1994; 11:1809–1814.

92.

Prausnitz

Pliquett

Langer

. Rapid temporal control of transdermal drug delivery by electroporation. Pharm Res 1994; 11:1834–1837.

93.

Vanbever

Le Boulengé

Préat

. Transdermal delivery of fentanyl by electroporation. I. Influence of electrical factors. Pharm Res 1996; 13:559–565.

94.

Vanbever

Skrypczak Jadoul

. Comparison of electroperturbations induced by iontophoresis and electroporation. In: Brain

James

Walters

, eds. Prediction of percutaneous penetration, Vol. 4. Cardiff: STS Publishing, 1996: 243–246.

95.

Camel

. Ultrasound. In: Smith

Maibach

, eds. Percutaneous penetration enhancement. Boca Raton: CRC Press, 1995:369–382.

96.

Bommannan

Okuyama

Stauffer

Guy

. Sonophoresis I. The use of high-frequency ultrasound to enhance transdermal drug delivery. Pharm Res 1992; 9:559–564.

97.

Benson

HAE

McElnay

. Transmission of ultrasound energy through topical pharmaceutical products. Physiotherapy 1988; 74:587–589.

98.

McElnay

Kennedy

Harland

. The influence of ultrasound on the percutaneous absorption of fluocinolone acetonide. Int J Pharm 1987; 40:105–110.

99.

Mitragotri

Edwards

Blankschtein

Langer

. A mechanistic study of ultrasonically-enhanced transdermal drug delivery. J Pharm Sci 1995; 84:697–706.

100.

Mitragotri

Blankschtein

Langer

. Transdermal drug delivery using low-frequency sonophoresis. Pharm Res 1996; 13: 411–420.

101.

Menon

Bommannan

Elias

. High-frequency sonophoresis: Permeation pathways and structural basis for enhanced permeability. Skin Pharmacol 1994; 7:130–139.

102.

Bommanan

Menon

Okuyama

. Sonophoresis II. Examination of the mechanism(s) of ultrasound-enhanced transdermal drug delivery. Pharm Res 1992; 9:1043–1047.

103.

Johnson

Mitragotri

Patel

. Synergistic effect of chemical enhancers and therapeutic ultrasound on transdermal drug delivery. J Pharm Sci 1996; 85:670–679.

104.

Mitragotri

Blankschtein

Langer

. Ultrasound-mediated transdermal protein delivery. Science 1995; 269:850–853.

105.

Tachibana

. Transdermal delivery of insulin to alloxan-diabetic rabbits by ultrasound exposure. Pharm Res 1992; 9:952–954.

106.

Benson

HAE

McElnay

Harland

. Phonophoresis of lignocaine and prilocaine from Emla cream. Int J Pharm 1988; 44:65–69.

107.

Brucks

Nanavaty

Jung

Siegel

. The effect of ultrasound on the in vitro penetration of ibuprofen through human epidermis. Pharm Res 1989; 6:697–701.

108.

Tennant

Moll

DePaulo

. Topical morphine for peripheral pain. Lancet 1993; 342:1047–1048.